H
Humacyte Inc (HUMA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$0.54
-0.02 (-3.24%)
Market Cap: $155.12M
Last updated: Nov 17, 2026 at 11:05 AM ET
Humacyte Inc (HUMA) Valuation Multiples
Humacyte (HUMA) trades at 62.6x sales and 8.3x book value. Its P/B of 8.3x is above its 5-year median of 6.2x. Its forward P/E is 35.8x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 35.8x |
| Price to sales | 62.6x |
| Price to book | 8.3x |
| PEG | N/A |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/B | 8.3x | 6.2x | N/A |
Valuation History
Over the 4 of the 5 year ends shown that have a P/S, its P/S ranged from 27.3x in 2023 to 138.9x in 2022.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $0.96 | 70.7x | 48.9x |
| 2024 | $5.05 | 82.8x | N/A |
| 2023 | $2.84 | 27.3x | 21.7x |
| 2022 | $2.11 | 138.9x | 1.9x |
| 2021 | $7.25 | N/A | 6.2x |
Frequently Asked Questions About HUMA
What is HUMA's forward P/E ratio?
Humacyte has a forward P/E ratio of 35.8x.
What is HUMA's price to sales ratio?
Humacyte has a price to sales ratio of 62.6x.
HUMA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors